Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab

This study is testing nivolumab — an immune checkpoint immunotherapy drug — for people with olfactory neuroblastoma (a rare cancer that starts in the nerve cells lining the nasal cavity) that has come back or spread after prior chemotherapy and cannot be treated with surgery or radiation. **You may be eligible if...** - You are 18 or older - You have confirmed olfactory neuroblastoma - Your cancer has returned or spread and cannot be treated with surgery or radiation - You have already received chemotherapy and your cancer has progressed - You have at least one measurable tumor on scans - Your general health is good (ECOG 0–1) - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have another active primary cancer - You have a systemic infection requiring treatment - You are known to have HIV or AIDS - You have active autoimmune disease requiring systemic treatment - You have interstitial lung disease (lung scarring) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.